Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Xlife Sciences AG, CH0461929603

Xlife Sciences AG, CH0461929603

26.11.2019 - 08:36:57

Xlife Sciences AG: New project in the portfolio

We are pleased to announce that Xlife Sciences AG has added Araxa Biosciences GmbH to the port-folio.

Araxa Biosciences GmbH

For certain diseases, no potent cure or diagnostics exist. Great hope lays in protein-based pharmaceuticals such as antibody-drug conjugate (ADC) or radioimmunotherapy for cancer. The high biological specificity is a critical advantage compared to typical small synthetic pharmaceutical ingredients; it allows the treatment to focus only on the cancer cells and thereby reducing side effects. Targeted chemical modification is used to enhance the effectiveness, and other characteristics of antibodies. It is also not only one of the most promising, but also, most technical advanced development areas of biotechnology. Most common methods for production of protein-small molecule conjugates suffer from drawbacks such as bulky modifications, restriction of the modification site, complex and inefficient procedures, batch-to-batch variety or a high expenditure of time.

Araxa Biosciences GmbH is a spin-off from Europe's most prestigious life science research institute, the European Molecular Biology Laboratory (EMBL) in Heidelberg. The company aims to develop a technology platform which overcomes all the limitations mentioned above. The concept is based on the precise side-specific injection of synthetic so-called unnatural amino-acids (UAA) in monoclonal antibodies through expansion of the genetic code. The UAA can be connected with active pharmaceutical ingredients or radioisotopes through bioorthogonal click chemistry in an ultrafast and quantitative manner - even inside cells and eventually in future patients. The modular concept allows to independently exchange antibodies or modification, enabling a fast change from nuclear diagnosis to ADC therapy. Araxa Biosciences GmbH will operate as a research and development-focused antibody engineering service provider and will consider developing a proprietary pharmaceuticals pipeline. For more information, please visit: www.araxa-biosciences.com

Xlife Sciences AG Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and futureoriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch

End of Media Release Issuer: Xlife Sciences AG Key word(s): Finance

26.11.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: Xlife Sciences AG Klausstrasse 19 8008 Zürich

Switzerland Phone: 0041 44 385 84 60 E-mail: info@xlifesciences.ch Internet: www.xlifesciences.ch ISIN: CH0461929603 Listed: Regulated Unofficial Market in Munich EQS News ID: 921357   End of News DGAP Media

921357  26.11.2019 

@ dgap.de